Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mefenamate is the carboxylate anion and active species derived from **mefenamic acid**, a fenamate nonsteroidal anti-inflammatory drug. In pharmacology and medicinal chemistry literature, \"mefenamate\" often refers specifically to the deprotonated ligand form present in salts and metal complexes, while in vivo the clinically used drug is mefenamic acid. Its principal therapeutic biology is inhibition of cyclooxygenase enzymes, reducing prostaglandin synthesis and thereby producing analgesic, anti-inflammatory, and antipyretic effects; fenamates have also been reported to modulate certain ion channels and, in experimental systems, mefenamate has been linked to cochlear NMDA receptor-mediated tinnitus biology indirectly through cyclooxygenase inhibition and altered arachidonic acid signaling. The provided sources mainly describe mefenamate as a chemical ligand or counterion in complexes, salts, and delivery materials rather than as a standalone proprietary development candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mefenamate.